Merrimack Pharmaceuticals, Inc. (MACK)

Oncology Corporate Profile

Stock Performance

7.2100
-0.1300

HQ Location

One Kendall Square, Suite B7201
Cambridge, MA 2139

Company Description

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six targeted therapeutic oncology therapeutics in clinical development.

Website: http://www.merrimackpharma.com

Brand Generic Indication
Onivyde__ยขirinotecan liposome injectionONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MM-398nanotherapeutic2nd line metastatic Pancreatic cancerIII
MM-398nanotherapeuticColorectal cancerIII
MM-111 (+ aclitaxel and trastuzumab)bi-specific antibody (anti-ErbB3 & anti-ErbB2) 2nd line metastatic Gastric cancerII
MM-121 (+ paclitaxel)anti-erbb3 monoclonal antibodyBreast cancerII
MM-121 (+ exemestane)anti-erbb3 monoclonal antibodyBreast cancerII
MM-302nanotherapeuticBreast cancer (HER2+)II
MM-121 (+ erlotinib)anti-erbb3 monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)II
MM-121 anti-erbb3 monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)II
MM-121 (+ paclitaxel)anti-erbb3 monoclonal antibodyOvarian cancerII
MM-398nanotherapeuticGliomaI
MM-398nanotherapeuticPediatric cancerI
MM-141bi-specific tetravalent antibody (ErbB3 & IGF-1R)Various cancer typesI
MM-141 (+ everolimus and docetaxel)bi-specific tetravalent antibody (ErbB3 & IGF-1R)Various cancer typesI
MM-310antibody-directed nanotherapeutic (ADN)Various cancer typesI
MM-151anti-egfr oligoclonal antibodyVarious cancer typesI
MM-131multispecific antibodyVarious cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.merrimackpharma.com

Recent News Headlines

Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting

3/27/2017 11:00 am

[PR Newswire] - CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data from its oncology pipeline at the 2017 ...

Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors

3/23/2017 11:00 am

[PR Newswire] - CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. "The initiation of this study is an important step in evaluating MM-310's safety and preliminary activity in patients diagnosed with solid tumors," said Vasileios Askoxylakis, MD, PhD, Medical Director and MM-310 Project Leader at Merrimack.

Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena Pharmaceuticals and Merrimack Pharmaceuticals

3/8/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 8, 2017 / Biotech and Pharmaceutical companies were under attack Tuesday after President Trump tweeted, "I am working on a new system where there will be competition ...

Merrimack reports 4Q loss

3/1/2017 12:02 pm

Merrimack reports 4Q loss

3/1/2017 12:02 pm

Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results

3/1/2017 12:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its fourth quarter and full year 2016 financial results for the period ended December 31, ...

Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call

2/22/2017 09:00 pm

[PR Newswire] - The call will cover an update on Merrimack's recent progress as well as a summary of fourth quarter and full year 2016 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts.